Search This Blog

Thursday, November 21, 2019

GlycoMimetics sinks 20% after delaying trial top-line

GlycoMimetics (NASDAQ:GLYC) plunges 20% after disclosing that it now expects top-line results from its Phase 3 clinical trial of uproleselan in relapsed/refractory AML in 2021.
Had previously expected results at 2020 end.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)